FDA removes patient-identifiable RWE requirement for device submissions

FDA removes patient-identifiable RWE requirement for device submissions

The FDA has eliminated the requirement for patient-identifiable data in real-world evidence (RWE) submissions for medical devices. This policy shift recognizes that previous mandates made it impractical to utilize vast, high-value databases containing macro-level insights. By accepting de-identified data, the agency acknowledges that large-scale records offer critical views into treatment outcomes that traditional clinical trials cannot capture. This change unlocks access to extensive repositories, including cancer registries and electronic health record networks. These resources contain millions of patient records that reflect real-world treatment settings, allowing researchers to identify relevant variables more efficiently. The move aims to reduce costs and accelerate the development of life-changing therapies by removing unnecessary barriers to data utilization. Relevance to open data lies in the validation of anonymized datasets as primary sources for regulatory decision-making. This precedent encourages the broader adoption of open, de-identified health data ecosystems. It signals a global shift toward trusting large-scale, privacy-compliant data sharing to enhance public health innovation and regulatory transparency.

Related news

• FDA to Accept De-Identified Real-World Evidence for Select Medical Device Applications | AJMC
• La Diputación de Valladolid estrena un portal de transparencia más accesible e intuitivo y que mejora su buscador
• The Bureau of Labor Statistics published new employment data. Here's how unemployment and job growth looked in November.
• First multimodal medical dataset launched to capture patient-clinician interactions
• La Diputación de Valladolid refrenda su compromiso con la transparencia, la accesibilidad y el gobierno abierto con un nuevo portal web